The world is waiting with bated breath for a coronavirus vaccine, which has become one of the most sought-after pharmaceutical products of the last century.
Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients.
Thousands of patients have signed up in a few days to support a large-scale NHS trial for potential treatments for COVID-19 in the UK, one of the countries worst hit by the global pandemic.
The FDA has backed the first COVID-19 diagnostic with a home collection option, at a time when the US is struggling to keep pace with the pandemic and suffering from a shortage of tests.
Novartis has announced plans to begin a large-scale trial of hydroxychloroquine in patients hospitalised with COVID-19, which could give a definitive answer about whether th
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.